Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irreversible Electroporation

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary management of localized resectable pancreatic cancer. Cancers. 2018;10(1):24. doi:10.3390/cancers10010024
   PubMed Web of Science ®Google Scholar
• Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14(4):1320–1326. doi:10.1245/s10434-006-9249-8
   PubMed Web of Science ®Google Scholar
• Abrams RA, Lowy AM, O’Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16(7):1751–1756. doi:10.1245/s10434-009-0413-9
   PubMed Web of Science ®Google Scholar
• Kang H, Jo JH, Lee HS, et al. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol. 2018;10(11):421–430. doi:10.4251/wjgo.v10.i11.421
   PubMed Web of Science ®Google Scholar
• Barenboim A, Lahat G, Geva R, et al. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis. Eur J Surg Oncol. 2018;44(10):1619–1623. doi:10.1016/j.ejso.2018.07.057
   PubMed Web of Science ®Google Scholar
• Xie DR, Yang Q, Chen DL, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol. 2010;40(5):432–441. doi:10.1093/jjco/hyp198
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern cooperative oncology group trial. J Clin Oncol. 2011;29(31):4105–4112. doi:10.1200/JCO.2011.34.8904
   PubMed Web of Science ®Google Scholar
• Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–1853. doi:10.1001/jama.2016.4324
   PubMed Web of Science ®Google Scholar
• He C, Huang X, Zhang Y, Cai Z, Lin X, Li S. Comparison of survival between irreversible electroporation followed by chemotherapy and chemotherapy alone for locally advanced pancreatic cancer. Front Oncol. 2020;10:6. doi:10.3389/fonc.2020.00006
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Zhang Y, Lin X, Li S. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: a propensity score matching analysis. Pancreatology. 2020;20(3):477–484. doi:10.1016/j.pan.2020.02.009
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Sun S, et al. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. BMC Cancer. 2019;19(1):394. doi:10.1186/s12885-019-5607-3
   PubMedGoogle Scholar
• Ruarus AH, Vroomen L, Geboers B, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology. 2020;294(1):212–220. doi:10.1148/radiol.2019191109
   PubMed Web of Science ®Google Scholar
• Holland MM, Bhutiani N, Kruse EJ, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB. 2019;21(8):1024–1031. doi:10.1016/j.hpb.2018.12.004
   PubMed Web of Science ®Google Scholar
• Martin RC, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262(3):486–494. doi:10.1097/SLA.0000000000001441
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma version 1, 2020; 2020. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed April 22, 2021.
   Google Scholar
• Huang X, He C, Lin G, et al. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 2020;524(4):1064–1071. doi:10.1016/j.bbrc.2020.02.042
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Zhang Y, Cai Z, Lin X, Li S. Comparison of combination therapies in the management of locally advanced pancreatic cancer: induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. Cancer Med. 2020;9(13):4699–4710. doi:10.1002/cam4.3119
   PubMed Web of Science ®Google Scholar
• He C, Wang J, Sun S, Zhang Y, Li S. Immunomodulatory effect after irreversible electroporation in patients with locally advanced pancreatic cancer. J Oncol. 2019;2019:9346017. doi:10.1155/2019/9346017
   PubMed Web of Science ®Google Scholar
• Shen ZT, Zhou H, Li AM, et al. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. J Cancer Res Clin Oncol. 2020;146(2):417–428. doi:10.1007/s00432-019-03066-z
   PubMed Web of Science ®Google Scholar
• Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–347. doi:10.1097/SLA.0000000000002753
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Stam AGM, Geboers B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology. 2019;8(11):1652532. doi:10.1080/2162402X.2019.1652532
   PubMed Web of Science ®Google Scholar
• Lang D, Horner A, Brehm E, et al. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study. Lung Cancer. 2019;134:59–65. doi:10.1016/j.lungcan.2019.05.033
   PubMed Web of Science ®Google Scholar
• Hwang HK, Kim HI, Kim SH, et al. Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3(+))/activated cytotoxic T lymphocyte (granzyme B(+)) ratio on resected left-sided pancreatic cancer. Oncol Lett. 2016;12(6):4477–4484. doi:10.3892/ol.2016.5252
   PubMed Web of Science ®Google Scholar
• He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med. 2020;10:e39.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zoltan M, Riquelme E, et al. Immune cell production of interleukin 17 induces stem cell features of pancreatic intraepithelial neoplasia cells. Gastroenterology. 2018;155(1):210–223.e213. doi:10.1053/j.gastro.2018.03.041
   PubMed Web of Science ®Google Scholar
• Parriott G, Deal K, Crean S, Richardson E, Nylen E, Barber A. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. Immunology. 2020;160(3):280–294. doi:10.1111/imm.13187
   PubMed Web of Science ®Google Scholar
• Li X, Huang Q, Hu X, et al. Evaluating the osteoimmunomodulatory properties of micro-arc oxidized titanium surface at two different biological stages using an optimized in vitro cell culture strategy. Mater Sci Eng C. 2020;110:110722. doi:10.1016/j.msec.2020.110722
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen X, Tian L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10(1):899. doi:10.1038/s41467-019-08782-1
   PubMed Web of Science ®Google Scholar
• Pandit H, Hong YK, Li Y, et al. Evaluating the regulatory immunomodulation effect of irreversible electroporation (IRE) in pancreatic adenocarcinoma. Ann Surg Oncol. 2019;26(3):800–806. doi:10.1245/s10434-018-07144-3
   PubMed Web of Science ®Google Scholar